TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02935465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study: NCT04585516

Intervention type: PROCEDURE
Intervention: endoscopy
Description: Colonoscopy or gastroscopy

Intervention type: PROCEDURE
Intervention: endoscopy
Description: Colonoscopy or gastroscopy
Study: NCT00668603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol hemihydrate
Description: 1 mg skin gel daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol hemihydrate
Description: 1 mg skin gel daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill + gel
Description: placebo daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill + gel
Description: placebo daily for 6 months
Study: NCT02117180

Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP's diet
Description: The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
Study: NCT01168024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CINCOR™ System and contrast conservation unit (CCS-1)
Description: Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care plus peri-procedural hydration
Description: The control group will receive a peri and post-procedural hydration rate.
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study: NCT00321867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graft augmented posterior repair
Description: Posterior repair with graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Native tissue repair
Study: NCT04647123

Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Study: NCT04274985

Intervention type: OTHER
Intervention: Questionnaire application
Description: Patients will complete the mentioned questionnaires.
Study: NCT02647021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic + Lower Body Exercise
Description: A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
Study: NCT00984386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal placebo, 100μl administered once before punch biopsy
Study: NCT00942669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStrip OTC(TM)
Description: self contained SAS screening device
Study: NCT02471898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02631434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sit-to-stand test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: six-minutes walking test
Study: NCT03702192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR
Description: novel antithrombotic management protocol
Study: NCT03993314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
Study: NCT04501874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMB-001
Description: 720 mg metyrapone/24 mg oxazepam mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMB-001 Placebo
Description: Inactive comparator
Study: NCT00519090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)
Description: Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
Study: NCT01864746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib PD-0332991
Description: palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
Study: NCT03029572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet supplementation
Description: Micronutriment supplementation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass provided in both arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass provided in both arms.
Study: NCT02473341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated.
Study: NCT02889926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a swab according to the method of Levine
Description: A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological referred to biopsy
Description: Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
Study: NCT01319422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Comparison of different dosages and schedules of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Comparison of different dosages and schedules of drug
Study: NCT02361307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seamless ADL training
Description: The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ADL training
Description: The control group receive the conventional ADL training programme
Study: NCT00592423

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Positive Airway Pressure during MRI
Description: 10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
Study: NCT00784225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: 200 mcg daily for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: 200 mcg daily for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 400 IU daily by mouth for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 400 IU daily by mouth for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E placebo
Description: daily for 7-12 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin E placebo
Description: daily for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: daily for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: daily for 7-12 years
Study: NCT04352101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
Study: NCT04767399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: protaper next
Description: rotary systems used on patients need root canal treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: protaper next
Description: rotary systems used on patients need root canal treatment
Study: NCT04647123

Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)

Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)

Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Study: NCT02561442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Study: NCT01378767

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Krill oil supplementation
Description: During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil supplementation
Description: During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
Study: NCT00784225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selenium placebo
Description: daily for 7-12 years
Study: NCT03529981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuned Vibroacoustic Stimulation (TVS)
Description: TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no active intervention
Description: No intervention will be administered
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study: NCT02531061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes.
Study: NCT04318626

Intervention type: DRUG
Group type: OTHER
Intervention: PMPBB3
Description: F-18 PMPBB3 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: PMPBB3
Description: F-18 PMPBB3 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: THK5351
Description: F-18 THK5351 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: THK5351
Description: F-18 THK5351 PET Imaging
Study: NCT00015912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02620228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP Biopsy System
Description: BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
Study: NCT01061073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omexel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spasfon
Study: NCT02377258

Intervention type: OTHER
Intervention: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional
Study: NCT03684499

Intervention type: OTHER
Group type: OTHER
Intervention: fluid supplementation
Description: The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.

Intervention type: OTHER
Group type: OTHER
Intervention: breast feeding
Description: The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
Study: NCT00845598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine , fluticasone
Description: Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
Study: NCT03809962

Intervention type: DEVICE
Intervention: Ostenil® Plus
Description: Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
Study: NCT02525497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FM peritoneal dialysis machine
Description: FM peritoneal dialysis machine APD 10L/10h

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOMECHOICE peritoneal dialysis machine
Description: HOMECHOICE peritoneal dialysis machine APD 10L/10h
Study: NCT01912521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mfangano Health Net Microclinic Program
Description: Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
Study: NCT03019809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF for Conditioning before HSCT.
Description: Mobilization of hematopoietic stem (HSC) into circulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plerixafor for Conditioning before HSCT.
Description: Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
Study: NCT03717558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin T2
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T2
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T2
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T2
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin T3
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T3
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T3
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T3
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
Study: NCT01315418

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 2-Non fermented dairy product (control)
Study: NCT02436993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
Study: NCT01030302

Intervention type: DRUG
Intervention: bortezomib
Description: bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days